Additional tests
Vitamin D, long-term blood sugar (HbA1c) and gut-health markers complement BalanceTest.
Our perspective · Zinzino
Why Zinzino?
Science. Substance. Shared ambition.
What do your own fatty acid levels reveal? The test-based approach helps you understand your starting point and changes at a follow-up test. Here, Sven and Audrey share the research, company fundamentals and personal experience behind their decision.
Nasdaq First North
Premier Growth Market
The people behind the company
Hilde & Ørjan Sæle.Experience that earns trust.
Hilde and Ørjan Sæle co-founded Zinzino in 2005 and bring decades of experience in direct selling. Sven and Audrey regard them as exceptional leaders and trusted people to work with, valuing their personal commitment, accessibility and long-term perspective.
A closer look, in three facts
The company at a glance.Perspective through evidence.
#20DSN Global 100 · 2026Product-focused companies · based on 2025 revenue+21%Group revenue growthJan–Sep 2026 · preliminary · year on year16.3%EBITDA marginQ2 2026 · reported
Company results for the periods shown; not individual partner earnings or a forecast.
01 / Science
ScienceA measurable starting point.
Zinzino combines BalanceOil+, an omega-3 food supplement, with a test-based approach to nutrition. BalanceTest measures 11 fatty acids, analysed by VITAS in Norway.
- Test
- Track
- Trust
BalanceOil+ is Informed Sport certified: every batch is tested for substances banned in sport, with publicly accessible batch numbers and test dates.
Test database · worldwide
1,928,049Worldwide fatty acid tests analysed
Company figure, 19 October 2026 · Tests, not unique individuals.
Zinzino describes itself as a global leader in test-based, personalised nutrition. This is the company’s positioning, not an independently verified market-share ranking.
Research · 9 August 2025
595,480Blood samples · global fatty-acid patterns
The 2025 study maps geographic and demographic differences in fatty-acid status. Users reporting Zinzino omega-3 supplements were excluded.
Earlier research · 2025Torrissen et al. · Lipids in Health and Disease · 2025 · DOI: 10.1186/s12944-025-02676-6New research · 15 October 2026
762,150Dried blood spot samples in peer-reviewed research
A closer look at real-world nutrition: this 2026 analysis compares fatty-acid profiles across three self-reported omega-3 supplementation groups. EPA+DHA and AA/EPA patterns differed between groups. For us, the interesting perspective is the move from broad categories to personal measurements.
Observational findings, not proof of product benefits. Author links to Zinzino/VITAS are disclosed. Testing does not replace medical assessment.
Original study · 2026Gisslevik et al. · Lipids in Health and Disease · 2026 · DOI: 10.1186/s12944-026-03071-5Press coverage · Finwire / MarketScreener · 19 October 2026Both studies use the same test database; samples may overlap. Do not add their counts.
Beyond omega-3.A whole-person approach.
Omega and balance are our starting point. From there, we consider nutrition, wellbeing and care together, with additional tests and products for different needs.
Gut health
Dietary fibre and complementary plant extracts for an everyday nutrition routine.
Nutrients & immune support
Vitamins, minerals and beta-glucans, including options for children.
Recovery & wellbeing
Complementary formulations with saffron or phycocyanin.
Weight & nutrition
Meal replacements and bars for a considered approach to everyday nutrition.
Skin, inside & out
Collagen products alongside cleansers, serums, creams and masks.
Together, we choose what fits your goals. Product availability varies by country.
Explore the range02 / Technology
TechnologyInnovation with a longer horizon.
The next chapter starts with microalgae.
Think beyond the next product: towards new ways of sourcing its ingredients. Through Xion, Zinzino is investing in algae technology, combining photobioreactors and fermentation. The ambition is a future omega-3 supply for BalanceOil+ — a development project that puts tomorrow’s raw materials on today’s agenda.
Production with purpose.
From an idea to consistent production, execution matters. BioActive Foods and Faun Pharma connect development and manufacturing within the group. Faun Pharma’s ISO 9001 certification and HACCP-based quality management give that work a structured foundation.
Intelligence in action.
Digital intelligence is already part of daily operations. In Q2 2026, Zinzino reported that AI handled 30% of customer-service enquiries. For us, that is a tangible sign of a business building its digital capabilities as it grows internationally.
30%Customer-service enquiries handled through AI · Q2 2026
NEW FRONTIERS IN PERSONALIZED WELLNESS
From test-based nutrition to fermented botanicals
Zinzino continues to expand its approach to personalized wellness with the European launch of three fermented botanical supplements: BelAge AM, Inner7 and KroNuit PM.
Unveiled at the 2026 Annual Event in Oslo, the new range combines botanical ingredients, fermentation technology and convenient drink formats designed for different moments of the day.
The launch represents another step in Zinzino’s product development strategy, connecting its established focus on test-based nutrition with new approaches to everyday wellness.
Financial research platform Simply Wall St covered the launch in its 27 October update, discussing the portfolio expansion and the commercial question of repeat usage.
Innovation is not just about creating new products. It is about making new possibilities accessible in everyday life.
Financial commentary, not scientific validation or an independent product recommendation.03 / Financial strength
Financial strengthGrowth with financial substance.
According to Zinzino’s preliminary sales report of 4 November 2026, Zinzino Group revenue for January–October 2026 was SEK 3,128.0 million, up 19% from the same period a year earlier. In October 2026, group revenue was SEK 328.7 million, up 1% from October 2025. The Q2 report also records positive operating cash flow and a substantial cash balance.
October 2026 sales report842.0million SEK
Cash & equivalents · 30 June 2026
280.0million SEK
Operating cash flow · H1 2026
Company results for the periods shown; not individual partner earnings or a forecast.
Research and production in the group
Zinzino owns BioActive Foods and Faun Pharma, connecting product development and manufacturing.
A business continuously moving forward.
Q3 2026 sales-market growth reached 48% in Asia-Pacific and 55% in North America. Expansion is visible in the numbers, with performance varying by region.
Asia-Pacific+48%
North America+55%
Q3 2026 sales-market revenue · year-on-year growth04 / Together
Stronger together.What connects us.
Leadership grows where people trust one another, learn from each other and take responsibility. The 2026 Ambassador Trip captures a moment of that shared journey.
BRAVO IMPACT AWARD / 2026
Recognition beyond the company.
Direct Selling News awarded Zinzino its 2026 Bravo Impact Award.
Direct Selling News · Bravo Impact Award 2026 ↗A closer look is worthwhile.See for yourself.
Explore Zinzino through Sven and Audrey’s personalized company page.
Explore Zinzino with usSven and Audrey Goebel are independent Zinzino Partners and shareholders. Purchases through their links may earn them commissions. This is their personal website.